Gestational Diabetes Mellitus: NICE for the U.S.?: A comparison of the American Diabetes Association and the American College of Obstetricians and Gynecologists guidelines with the U.K. National Institute for Health and Clinical Excellence guidelines by Simmons, David et al.
Gestational Diabetes Mellitus: NICE for the
U.S.?
A comparison of the American Diabetes Association and the American
College of Obstetricians and Gynecologists guidelines with the U.K.
National Institute for Health and Clinical Excellence guidelines
DAVID SIMMONS, FRCP, MD
1
AIDAN MCELDUFF, PHD, FRACP
2 HAROLD DAVID MCINTYRE, FRACP
3
MOHAMED ELRISHI, MRCP
4
OBJECTIVE — To compare recent U.S. and U.K. guidelines on gestational diabetes mellitus
(GDM).
RESEARCH DESIGN AND METHODS — The guidelines from the American Diabetes
Association,theAmericanCollegeofObstetriciansandGynecologists,andtheNationalInstitute
for Health and Clinical Excellence (NICE) in the U.K. were collated and compared using a
general inductive approach.
RESULTS — There are substantial differences in the recommendations between the U.K. and
theU.S.guidelines.Ofparticularnotearethereducedsensitivitiesoftheearlyandlaterantenatal
and postnatal screening and diagnostic criteria. NICE undertook a cost-effectiveness analysis
using lower prevalence estimates and limited outcomes and still showed screening for GDM to
be cost-effective.
CONCLUSIONS — The latest NICE recommendations appear to reduce access to proven,
cost-effective management of GDM, an issue relevant in the current U.S. health care policy
debate.
Diabetes Care 33:34–37, 2010
I
n an age of increasing patient empow-
erment, the diagnosis of gestational di-
abetes mellitus (GDM) provides a
woman with the knowledge that her baby
has an increased chance of complications
before, during, and after birth (including
an increased chance of obesity and/or di-
abetes in the future); that she herself has
an increased chance of future diabetes;
and that future pregnancies are more
likely to be complicated by diabetes (ges-
tational or otherwise) (1). Such knowl-
edge could be harmful if there were no
opportunities to reduce these risks. How-
ever, there is now good evidence that
there are fewer obstetric and neonatal
complications with intensive manage-
ment (2) and that future diabetes cases
can be delayed and possibly avoided (3).
There is even evidence that there may be
fewer incidents of postnatal depression
following the diagnosis and management
of GDM than among untreated women
(2). To further the recent debate on the
screeninganddetectionofGDM(4,5),we
have compared the different approaches
tothedetectionandmanagementofGDM
recommended by the American Diabetes
Association (ADA) (6), the American Col-
lege of Obstetricians and Gynecologists
(ACOG) (7), and the National Institute
forHealthandClinicalExcellence(NICE)
in the U.K. (8).
NICE is wholly funded by the U.K.
government to provide “national guid-
ance on promoting good health and pre-
venting and treating ill health.” NICE
assessments are multidisciplinary and in-
clude both research and health economic
considerations, the latter giving a Na-
tional Health Service, rather than a soci-
etal,perspective.NICEclinicalguidelines
for diabetes in pregnancy (8) were ini-
tially published in March 2008 and re-
visedinJuly2008,andabriefcritiquewas
published in September 2008 (9).
RESEARCH DESIGN AND
METHODS— The guidelines from
the three organizations were collated and
compared using a general inductive ap-
proach. Each guideline category has been
treated as a “theme.”
RESULTS— Table 1 compares the
ADA, ACOG, and NICE guidelines for dia-
betes in pregnancy (6–8). There are sub-
stantialdifferencesintherecommendations
between the U.K. and U.S. guidelines in
most categories.
Unlike NICE, the ADA and ACOG
guidelines do not include a cost-
effectiveness component. NICE used a
single cost-effectiveness model address-
ing screening, diagnosis, and treatment,
and the model was used to direct the
guideline recommendations. Using the
data from the Australian Carbohydrate
Intolerance Study in Pregnant Women
(ACHOIS) (2), NICE demonstrated that
thescreening,diagnosis,andtreatmentof
GDM are cost-effective.
CONCLUSIONS — This comparison
of NICE, ADA, and ACOG guidelines has
identiﬁed a number of key areas where
the recommendations are markedly di-
vergent. Of particular importance are:
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ADA ACOG NICE
Who should be
screened for GDM
Women at high risk of GDM should
undergo GTT as soon as feasible. If
found not to have GDM at initial
screening, they should be retested
between 24 and 28 weeks. Women of
average risk should have testing
undertaken at 24–28 weeks. Low-risk
status requires no glucose testing.
Because only 10% of the
population would be exempt
from screening using the
selective method, screen all
pregnant women (universal
screening) as a more practical
approach.
BMI 30 kg/m
2, previous baby
4.5 kg, previous GDM,
ﬁrst-degree relative with
diabetes, South Asian, black
Caribbean, Middle Eastern.
Not included are age, other
high-risk ethnic groups, past
IGT, polycystic ovarian
syndrome.
What women should be
told about screening
and testing for GDM
Although uncomplicated GDM with less
severe fasting hyperglycemia has not
been associated with increased perinatal
mortality, GDM of any severity increases
the risk of fetal macrosomia.
Women with GDM are more likely
to develop hypertensive
disorders than women without
GDM. GDM increases the risk of
fetal macrosomia. In addition,
women with GDM have an
increased risk of developing
diabetes later in life.
Most women respond to diet/
exercise; some (10–20%)
need other agents; if GDM is
not detected, there is a small
risk of birth complications
such as shoulder dystocia;
GDM may lead to more
interventions.
How screening for
GDM should occur
Women at high risk of GDM should
undergo GTT as soon as feasible. If they
are found not to have GDM at that
initial screening, they should be retested
between 24 and 28 weeks’ gestation.
Women of average risk should have
testing undertaken at 24–28 weeks’
gestation. Low-risk status requires no
glucose testing.
Universal screening by two-step
method. It involves an initial
test after administration of 50-g
glucose 1-h test followed by
GTT to conﬁrm the diagnosis
for patients with an abnormal
initial result.
75-g 2-h OGTT at 16–18
weeks if prior GDM; 24–28
weeks if risk factors
Criteria for GDM 100-g glucose: plasma glucose level (2 or
more time points need to elevated):
100-g glucose: plasma glucose
level (2 or more time points
need to elevated):
75-g glucose: plasma glucose
level (1 or more time points
need to elevated):
Fasting 5.3 mmol/l; Fasting 5.3 mmol/l; Fasting 7.0 mmol/l;
1-h 10.0 mmol/l; 1-h 10.0 mmol/l; 2-h 7.8 mmol/l
2-h, 8.6 mmol/l (only2hi f75-g
glucose used);
2-h, 8.6 mmol/l;
3-h, 7.8 mmol/l 3-h, 7.8 mmol/l
Screening for
undiagnosed type 2
diabetes
Women at high risk of GDM should
undergo GTT as soon as feasible.
Diagnosis of diabetes
recommended in the ﬁrst half of
pregnancy using 50-g 1-h
screening test
Early testing of blood glucose
or OGTT for women with a
history of GDM and/or IGT
(18–20 weeks)
Targets for blood
glucose control
Fasting whole blood glucose 5.3 mmol/l Plasma glucose level: Fasting 3.5–5.9 mmol/l
1-h postprandial whole blood glucose
7.8 mmol/l
Fasting, 5.3 mmol/l 1-h postprandial 7.8 mmol/l
2-h postprandial whole blood glucose
6.7 mmol/l
1-h postprandial, 7.2 mmol/l No A1C 2nd/3rd trimester
GDM antenatal
management
All women with GDM should receive
nutritional counseling. BMI 30 kg/m
2,
a 30–33% calorie restriction to 25
kcal/kg actual weight per day. Selection
of pregnancies for insulin therapy can
be based on measures of maternal
glycemia with or without assessment of
fetal growth characteristics. Inadequate
information to recommend oral
hypoglycemic agents.
Nutritional intervention in women
with GDM should be designed to
achieve normal glucose levels to
avoid ketosis. Hypoglycemic
therapy supported: further studies
recommended for glyburide.
Insulin therapy based on
measures of maternal glycemia
based on fasting, 1- and 2-h
postprandial.
Low GI diet, calorie restriction
if BMI 27 kg/m
2, moderate
exercise, hypoglycemic
therapy (including
metformin) after 1–2 weeks
if lifestyle insufﬁcient or
abdominal circumference
70th centile at diagnosis.
GDM intrapartum
management
Delivery during the 38th week is
recommended unless obstetric
considerations dictate otherwise.
Prolongation of gestation past 38 weeks
increases the risk of fetal macrosomia
without reducing cesarean rates.
The timing of delivery in GDM
remains relatively open. If
estimated fetal weight is 4,500 g
or more, cesarean delivery may
be considered.
Induce/elective cesarean after
38 weeks if normally grown
fetus; glucose monitoring
hourly target 4–7 mmol/l if
higher intravenous
dextrose/insulin
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Therecentpoint-counterpoint(4,5)com-
prehensively debated is in regards to
whether screening for GDMshould be se-
lective (i.e., using risk factors) or univer-
sal (i.e., using blood tests). There was
general agreement on the risk factors of
importance,whilethelatteraddressedthe
broader issues of complexity and long-
term beneﬁts. NICE recommendations
exclude several risk factors, including
some shown to be cost-effective. NICE
cost-effectiveness analysis substantially
understated the beneﬁts of screening be-
cause the basic decision tree structure
omitted many avoidable downstream
costs including some maternal morbidity
(e.g., preeclampsia), neonatal morbidity
(e.g., hypoglycemia), long-term maternal
morbidity (e.g., preventable complica-
tions by earlier diabetes diagnosis and in-
tervention), and long-term offspring risk
(e.g., fetal morbidity if undiagnosed dia-
betesinasubsequentpregnancy;possibly
future obesity and diabetes) (10).
NICE cost-effectiveness analysis ac-
knowledged that a large number of as-
sumptions were made “owing to data
limitations and methodological complex-
ity” and that there was potential for un-
derestimating the true costs and effects
(by using a cohort excluding those with
worseglucosecontrol)(2).Thepublished
modeling showed that universal screen-
ing becomes more cost-effective as the
disease prevalence increases and used a
sensitivity analysis with prevalence esti-
mates of GDM ranging from 2–5%; actual
GDM prevalence is now running at least
5–8% (1).
Detecting undiagnosed type 2
diabetes
Women with undiagnosed type 2 diabe-
tes are signiﬁcantly more prone to have
babies with malformations and may have
established diabetic complications (e.g.,
nephropathy and retinopathy) requiring
closefollow-uptoensurepromptrestora-
tionofnormoglycemia.NICErecommen-
dations delay the time to testing and
ignore important criteria (e.g., strong
family history). Given the often asymp-
tomatic nature of type 2 diabetes and its
potential to cause severe pregnancy com-
plications, we consider that testing
should be undertaken early in those at
high risk, ideally as part of the ﬁrst ante-
natal contact.
Postnatal testing
NICE dependence on fasting plasma glu-
cose screening without performing an
oral glucose tolerance test (OGTT) has
been shown to reduce the sensitivity of
identifying postpartum diabetes and im-
paired glucose tolerance (IGT) by 38–
60% (11–12). In another study, 83% of
those with IGT and 56% of those with
diabetes would have been missed (13).
The follow-up of women with a history of
GDM is becoming increasingly important
because of their increased risk of progres-
sion to type 2 diabetes (1) and the secular
trend for a shortening of time between
GDM and the development of diabetes
(14). Many of these women would have
been diagnosed at OGTT on the 2-h glu-
cose alone, avoiding the risk of undiag-
nosed diabetes at the next pregnancy
(shouldoneoccur).Moreover,withoutan
OGTT, IGT cannot be identiﬁed. This is
particularly important given the clear ev-
idence that progression to subsequent di-
abetes can be reduced by over 50% (3).
Among increasingly empowered,
knowledgeable, and “Internet savvy” pa-
tients, clinicians run the risk of having
their management undermined by con-
ﬂictingguidelines,makingtheimplemen-
tation of clinical care substantially harder
and more time-consuming. NICE guide-
lines are a relatively new addition to the
scene but appear to be the most minimal-
ist in relation to screening and postnatal
follow-up (1). Fortunately, the comple-
tion of the Hyperglycemia and Adverse
Pregnancy Outcomes (HAPO) study (15)
nowprovidesalargeobservationalcohort
that is being used to redeﬁne diagnostic
criteria for GDM in relation to adverse
outcomes.
In conclusion, the comparison be-
tween NICE, ADA, and ACOG guidelines
has demonstrated signiﬁcant differences
inrecommendationsforthescreening,di-
agnosis, and management of GDM. Cost-
effective management is a major issue in
the debate on health care reform in the
U.S., and current NICE recommenda-
tions appear to reduce access to proven,
cost-effective GDM management.
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